TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22181006

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.05 μg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.08 μg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.10 μg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20105045

Group type: EXPERIMENTAL
Intervention: Bolus administered 15 min before meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bolus administered just before meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bolus administered just after meal
Number of subjects: 30
Study: 17405792

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 307
Study: 16149831

Group type: EXPERIMENTAL
Intervention: Flap procedure
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sphincter pharyngoplasty
Number of subjects: 97
Study: 12151162

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10073326

Group type: EXPERIMENTAL
Intervention: Trimetrexate, leucovorin, and dapsone administered for 21 +/- 3 days; trimetrexate glucuronate, 45 mg/m2; leucovorin, 20 mg/m2; dapsone, 100 mg daily
Number of subjects: 0
Study: 7658230

Group type: EXPERIMENTAL
Intervention: New analytic procedure requiring six plasma samples for CMRglc measurement.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional method requiring 30 or more plasma samples for CMRglc measurement.
Number of subjects: 0
Study: 2291659

Group type: EXPERIMENTAL
Intervention: Cefmetazole 0.5 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefmetazole 1 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefmetazole 2 g
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cefmetazole (all doses)
Number of subjects: 24
Study: 7244426

Group type: EXPERIMENTAL
Intervention: 4% lidocaine hydrochloride
Number of subjects: 6

Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Comparison of bronchospasm after saline
Number of subjects: 6
Study: 31704504

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) + full-mouth ultrasonic scaling (FMUS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full-mouth ultrasonic scaling (FMUS) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (PDT + FMUS and FMUS alone)
Number of subjects: 30
Study: 30609761

Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (TENDOFORTE®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (collagen peptides and placebo)
Number of subjects: 20
Study: 28915426

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg i.v. in 50ml normal saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (50ml normal saline)
Number of subjects: 80
Study: 25872653

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behaviour therapy (TF-CBT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 44
Study: 24672232

Group type: EXPERIMENTAL
Intervention: C. domestica extracts 1,500 mg/day for 4 weeks
Number of subjects: 367

Group type: COMPARATOR
Intervention: Ibuprofen 1,200 mg/day for 4 weeks
Number of subjects: 367
Study: 21831100

Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 107

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 107
Study: 20683042

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Phenytoin (historical data from n=127 patients)
Number of subjects: 24
Study: 17055120

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (7.2 g/day, providing 1.1 g/day of 20:5 (n‐3) and 0.7 g/day of 22:6 (n‐3) fatty acids)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No supplementation (placebo)
Number of subjects: 15
Study: 15848572

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 122
Study: 12045833

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PYR) 45 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10465179

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg/day) for 6 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 7611726

Group type: EXPERIMENTAL
Intervention: Transfemoral, venous intradural infusions of urokinase
Number of subjects: 25
Study: 2171332

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (Premarin) 50 mg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6123336

Group type: COMPARATOR
Intervention: Fentanyl 0.0066 mg kg‐1 i.v. (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.0066 mg kg‐1 i.v. followed by almitrine 0.5 mg kg‐1 i.v. (group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of almitrine 0.5 mg kg‐1 and fentanyl 0.0066 mg kg‐1 (group C)
Number of subjects: 30
Study: 30296958

Group type: EXPERIMENTAL
Intervention: Irrational beliefs (IBs)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Rational beliefs (RBs)
Number of subjects: 81
Study: 28198997

Group type: EXPERIMENTAL
Intervention: Preoperative comprehensive geriatric assessment and optimization
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard preoperative assessment
Number of subjects: 176
Study: 26221410

Group type: EXPERIMENTAL
Intervention: Invisalign
Number of subjects: 152

Group type: COMPARATOR
Intervention: Braces
Number of subjects: 152
Study: 25620331

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no cardiac rehabilitation)
Number of subjects: 82
Study: 22134132

Group type: EXPERIMENTAL
Intervention: Solanezumab (0.5, 1.5, 4.0, and 10.0 mg/kg)
Number of subjects: 0
Study: 19864308

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion maintained at a target organ concentration of 1.5 ng ml‐1 until extubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (remifentanil infusion stopped at the end of surgery)
Number of subjects: 40
Study: 19074684

Group type: EXPERIMENTAL
Intervention: Functional Electric Stimulation (FES) with bilateral activities training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo stimulation with bilateral tasks
Number of subjects: 20
Study: 16319704

Group type: EXPERIMENTAL
Intervention: Treatment provided to high-stress group
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Treatment provided to low-stress group
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction for all patients
Number of subjects: 127
Study: 11972945

Group type: EXPERIMENTAL
Intervention: Teleconsultation (electronic consultation via a secure Web-based system)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (conventional referral letter to the hospital outpatient clinic)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Teleconsultation
Number of subjects: 93
Study: 9292630

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7659811

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 mcg vaginal tablet)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oxytocin (2‐32 mU/min i.v.)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study: 2444306

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg bd)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12473698

Group type: EXPERIMENTAL
Intervention: 1.50 mg/mL rhBMP-2
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 450
Study: 29487073

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus usual care (UC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 136
Study: 26506998

Group type: EXPERIMENTAL
Intervention: Anatomical tube
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard endotracheal tube
Number of subjects: 70
Study: 24357574

Group type: EXPERIMENTAL
Intervention: 1-day cognitive-behavioural therapy (CBT) self-confidence workshops
Number of subjects: 459

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 459
Study: 22416781

Group type: EXPERIMENTAL
Intervention: HIV-1 RNA genotyping
Number of subjects: 169

Group type: COMPARATOR
Intervention: HIV-1 DNA genotyping
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HIV-1 RNA
Number of subjects: 169

Group type: COMPARATOR
Intervention: HIV-1 DNA
Number of subjects: 169
Study: 20597564

Group type: EXPERIMENTAL
Intervention: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily for 24 or 48 weeks depending on genotype and weight
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 180 microg pegylated interferon‐alpha2a (Pegaferon) weekly and 800 - 1200 mg ribavirin daily
Number of subjects: 108
Study: 18414360

Group type: EXPERIMENTAL
Intervention: Propofol (0.4 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 15819826

Group type: EXPERIMENTAL
Intervention: Digident CAD/CAM system (DIGI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cerec Inlab system (INLA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lava system (LAVA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metal-ceramic FPDs (control)
Number of subjects: 24
Study: 12422331

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 27
Study: 10325515

Group type: EXPERIMENTAL
Intervention: Combined endocrine therapy for 3 or 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7567381

Group type: EXPERIMENTAL
Intervention: 5-trial practice group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-trial practice group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention session
Number of subjects: 0
Study: 2015969

Group type: EXPERIMENTAL
Intervention: recombinant DNA hGH (rhGH; 0.1 mg.kg‐1.day‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: prednisone (0.8 mg.kg‐1.day‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhGH and prednisone (combined treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: prednisone
Number of subjects: 32
Study: 6820207

Group type: EXPERIMENTAL
Intervention: CO2 laser conisation
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cold knife conisation
Number of subjects: 79
Study: 31569274

Group type: EXPERIMENTAL
Intervention: Microdose flare-up protocol
Number of subjects: 131

Group type: COMPARATOR
Intervention: Flare-up protocol
Number of subjects: 131

Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 131
Study: 30777511

Group type: EXPERIMENTAL
Intervention: Affective-context group (angry/happy faces)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral-context group (male/female faces)
Number of subjects: 0
Study: 28626020

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3 supplementation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 26854877

Group type: EXPERIMENTAL
Intervention: Removable partial dentures (n = 53) or implant‐supported fixed partial dentures (n = 19)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Removable partial dentures or implant‐supported fixed partial dentures (treatment group)
Number of subjects: 125
Study: 22958543

Group type: EXPERIMENTAL
Intervention: Autologous fibroblast-seeded artificial dermis (AFD) using animal-product-free medium
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Autologous fibroblast-seeded artificial dermis (AFD)
Number of subjects: 5
Study: 22438074

Group type: EXPERIMENTAL
Intervention: Native Hawaiian smokers
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Filipino and Native Hawaiian smokers
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Cessation interventions tailored for Native Hawaiian smokers
Number of subjects: 919
Study: 19641050

Group type: EXPERIMENTAL
Intervention: Colloid preload (500 mL of hydroxyethyl starch over 15-20 min before spinal anesthesia)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Colloid coload (identical fluid bolus of hydroxyethyl starch starting at the time of identification of cerebrospinal fluid)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Colloid preload
Number of subjects: 178

Group type: COMPARATOR
Intervention: Colloid coload
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Colloid preload and coload
Number of subjects: 178
Study: 17957416

Group type: EXPERIMENTAL
Intervention: Enhanced interpreter service intervention
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Spanish-speaking attending physician
Number of subjects: 323

Group type: COMPARATOR
Intervention: Usual interpreter services
Number of subjects: 323
Study: 15821354

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 8
Study: 11202125

Group type: EXPERIMENTAL
Intervention: Behavioural therapy (coping skills training and cognitive therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-specific supportive therapy
Number of subjects: 120
Study: 10360048

Group type: EXPERIMENTAL
Intervention: Combined vaginal Ovestin and GnRh analogues (Zoladex)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GnRh analogues alone (control group)
Number of subjects: 12
Study: 7846192

Group type: EXPERIMENTAL
Intervention: Oxazepam 40 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxazepam 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxazepam (20 and 40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2903659

Group type: EXPERIMENTAL
Intervention: Esmolol (n = 12), continuous intravenous infusion, titrated from 2 to 24 mg/min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propranolol (n = 11), oral, dose increased every 6 hours by 50 to 100%
Number of subjects: 23
Study: 30982351

Group type: EXPERIMENTAL
Intervention: Wheat samples (17 different samples, 670 g/kg of each wheat sample in diet)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Wheat samples (specific two samples)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Wheat samples (general)
Number of subjects: 800
Study: 27547871

Group type: EXPERIMENTAL
Intervention: Tapered corticosteroids (stopped after day 10)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: No steroids after intraoperative bolus
Number of subjects: 1081
Study: 26032567

Group type: EXPERIMENTAL
Intervention: Virtual reality job interview training (VR‐JIT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 32
Study: 23828748

Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balloon tamponade
Number of subjects: 20
Study: 21767283

Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5-50 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19801245

Group type: EXPERIMENTAL
Intervention: Composite resin restoration without post and cusp capping
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Composite resin restoration without post but with cusp capping
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Composite resin restoration with post but without cusp capping
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Composite resin restoration with post and cusp capping
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (intact teeth)
Number of subjects: 75
Study: 16895881

Group type: EXPERIMENTAL
Intervention: Butter-based diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: ROO, HPSO, butter, VEFO
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: VEFO omitted from analysis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Postprandial concentrations of triacylglycerol
Number of subjects: 14
Study: 15051213

Group type: EXPERIMENTAL
Intervention: Emulsion eye drop (EED)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonpreserved saline (Control)
Number of subjects: 15
Study: 10745146

Group type: EXPERIMENTAL
Intervention: Soft contact lens
Number of subjects: 0

Group type: COMPARATOR
Intervention: No contact lens (Control)
Number of subjects: 0
Study: 8814427

Group type: EXPERIMENTAL
Intervention: HIV-seropositive
Number of subjects: 100

Group type: COMPARATOR
Intervention: HIV-seronegative
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HIV-seropositive with advanced immunosuppression
Number of subjects: 100
Study: 1383618

Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg up to 100 mg daily)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg up to 80 mg daily)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 257
Study: 3905561

Group type: EXPERIMENTAL
Intervention: 750 mg D-penicillamine daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 250 mg D-penicillamine daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: D-penicillamine (both doses)
Number of subjects: 56
Study: 30832717

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-navigation (MI-NAV) intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care condition
Number of subjects: 80
Study: 27966575

Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combined Vitamin D2 and D3
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 26073333

Group type: EXPERIMENTAL
Intervention: Drospirenone-only pill
Number of subjects: 64

Group type: COMPARATOR
Intervention: Desogestrel-only pill
Number of subjects: 64
Study: 24360131

Group type: EXPERIMENTAL
Intervention: Cochlear implants
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 182

Group type: COMPARATOR
Intervention: Normal hearing (NH)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Sensorineural hearing loss (SNHL)
Number of subjects: 182
Study: 22801255

Group type: EXPERIMENTAL
Intervention: Simulation training on the vascular intervention simulation trainer simulator
Number of subjects: 21

Group type: COMPARATOR
Intervention: Expert evaluation
Number of subjects: 21
Study: 20003224

Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus optimal medical management
Number of subjects: 11

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 11
Study: 17524779

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplant (AMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conjunctival advancement
Number of subjects: 30
Study: 15334389

Group type: EXPERIMENTAL
Intervention: Pramlintide (60 microg subcutaneous premeal injections 3 times daily for 5 days, IV infusion of 16 microg/h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (subcutaneous premeal injections 3 times daily for 5 days, IV infusion of placebo)
Number of subjects: 18
Study: 12845247

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (22 g for 48 hours)
Number of subjects: 194
Study: 11829830

Group type: EXPERIMENTAL
Intervention: Rhodiola compound (RCO) 4 grams daily for 3-15 days after admission and 5-7 days post-operation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 104
Study: 8638026

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study: 1925418

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine 800 mg orally daily for six weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 7044411

Group type: EXPERIMENTAL
Intervention: 3% acyclovir (Zovirax)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 3% adenosine arabinoside (ara-A, Vidarabine)
Number of subjects: 93
Study: 3925464

Group type: EXPERIMENTAL
Intervention: l-histidine 3g/day for 7 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 29309971

Group type: EXPERIMENTAL
Intervention: Cognitive challenge (silent backward counting in steps of seven)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Visual perturbations (eyes open, eyes closed)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Surface perturbations (stable support, foam support)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Double-leg stance tests under challenging conditions
Number of subjects: 19
Study: 25147574

Group type: EXPERIMENTAL
Intervention: Real auricular point acupressure (APA) treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 37
Study: 22315389

Group type: EXPERIMENTAL
Intervention: Community-assisted strategy
Number of subjects: 39158

Group type: COMPARATOR
Intervention: Nurse-assisted strategy
Number of subjects: 39158
Study: 20961348

Group type: EXPERIMENTAL
Intervention: Pneumatic Skin Flattening (PSF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dynamic Cooling Device (DCD)
Number of subjects: 12
Study: 18485150

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 129314

Group type: COMPARATOR
Intervention: Single agent therapy
Number of subjects: 129314
Study: 16305291

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg twice/day for 14 days
Number of subjects: 14